Evogene Ltd. - Ordinary Shares (EVGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVGN Stock Summary
- EVGN has a higher market value than just 9.99% of US stocks; more precisely, its current market capitalization is $28,232,922.
- EVGN's price/sales ratio is 21.29; that's higher than the P/S ratio of 94.32% of US stocks.
- With a year-over-year growth in debt of 339.3%, EVOGENE LTD's debt growth rate surpasses 95.11% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to EVOGENE LTD are DARE, DRRX, SABS, PULM, and TMBR.
- EVGN's SEC filings can be seen here. And to visit EVOGENE LTD's official web site, go to www.evogene.com.
EVGN Valuation Summary
- EVGN's price/sales ratio is 21.2; this is 960% higher than that of the median Healthcare stock.
- EVGN's EV/EBIT ratio has moved up 93.5 over the prior 121 months.
Below are key valuation metrics over time for EVGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EVGN | 2022-11-25 | 21.2 | 0.9 | -0.9 | -0.3 |
| EVGN | 2022-11-23 | 21.3 | 0.9 | -0.9 | -0.3 |
| EVGN | 2022-11-22 | 20.4 | 0.9 | -0.9 | -0.3 |
| EVGN | 2022-11-21 | 21.1 | 0.9 | -0.9 | -0.3 |
| EVGN | 2022-11-18 | 22.3 | 1.0 | -1.0 | -0.4 |
| EVGN | 2022-11-17 | 23.0 | 1.0 | -1.0 | -0.4 |
EVGN Growth Metrics
- The 5 year net cashflow from operations growth rate now stands at -52.08%.
- Its 2 year net cashflow from operations growth rate is now at -55.96%.
- The 3 year net income to common stockholders growth rate now stands at -54.43%.
The table below shows EVGN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 1.011 | -28.257 | -32.077 |
| 2022-06-30 | 1.011 | -28.257 | -32.077 |
| 2022-03-31 | 0.834 | -27.734 | -29.466 |
| 2021-12-31 | 0.93 | -24.716 | -27.793 |
| 2021-12-31 | 0.93 | -24.839 | -27.793 |
| 2021-09-30 | 0.97 | -23.505 | -28.544 |
EVGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EVGN has a Quality Grade of D, ranking ahead of 9.47% of graded US stocks.
- EVGN's asset turnover comes in at 0.015 -- ranking 85th of 89 Chemicals stocks.
- 500 - Internal server error
The table below shows EVGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.015 | 0.448 | -2.136 |
| 2019-12-31 | 0.012 | 0.556 | -0.546 |
| 2018-12-31 | 0.026 | 0.169 | -0.317 |
| 2017-12-31 | 0.039 | 0.159 | -0.253 |
| 2016-12-31 | 0.063 | 0.138 | -0.203 |
| 2015-12-31 | 0.093 | 0.258 | -0.146 |
EVGN Price Target
For more insight on analysts targets of EVGN, see our EVGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
EVGN Stock Price Chart Interactive Chart >
EVGN Price/Volume Stats
| Current price | $0.65 | 52-week high | $2.14 |
| Prev. close | $0.68 | 52-week low | $0.63 |
| Day low | $0.65 | Volume | 51,721 |
| Day high | $0.71 | Avg. volume | 185,106 |
| 50-day MA | $0.75 | Dividend yield | N/A |
| 200-day MA | $0.97 | Market Cap | 26.85M |
Evogene Ltd. - Ordinary Shares (EVGN) Company Bio
Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company was founded in 1999 and is based in Rehovot, Israel.
Latest EVGN News From Around the Web
Below are the latest news stories about EVOGENE LTD that investors may wish to consider to help them evaluate EVGN as an investment opportunity.
Evogene (EVGN) Reports Q3 Loss, Tops Revenue EstimatesEvogene (EVGN) delivered earnings and revenue surprises of 20% and 79.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Evogene Reports Third Quarter 2022 Financial ResultsEvogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today its financial results for the third quarter, ended September 30, 2022. |
Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern AfricaCasterra Ag Ltd. ("Casterra"), the castor seeds technology developer whose mission is to provide the most advanced castor bean seed varieties and comprehensive ag-service solutions to castor cultivators and manufacturers, and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) ("Evogene"), announced today that it signed a long-term royalty agreement with Titan Castor Farms Limited ("Titan"), a Zambian cultivator, manufacturer and distributor of castor oil. |
Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 SummitBiomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17, 2022, in Boston, MA. |
Evogene Schedules Third Quarter of 2022 Financial Results Release & Conference Call for November 17, 2022Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development announced today that it will release its financial results for the third quarter of 2022 on Thursday, November 17, 2022. |
EVGN Price Returns
| 1-mo | -17.58% |
| 3-mo | -45.83% |
| 6-mo | -28.58% |
| 1-year | -67.98% |
| 3-year | -52.21% |
| 5-year | -83.03% |
| YTD | -60.37% |
| 2021 | -65.11% |
| 2020 | 209.21% |
| 2019 | -23.23% |
| 2018 | -35.50% |
| 2017 | -39.80% |
Continue Researching EVGN
Want to see what other sources are saying about Evogene Ltd's financials and stock price? Try the links below:Evogene Ltd (EVGN) Stock Price | Nasdaq
Evogene Ltd (EVGN) Stock Quote, History and News - Yahoo Finance
Evogene Ltd (EVGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...